Table 1 Proptosis graded response at week 24

From: Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis

 

Placebo (N = 45)

Teprotumumab (N = 42)

 

No. of subjects

%

No. of subjects

%

High response

4

8.90%

23

54.80%

Response

5

11.10%

7

16.70%

Low response

8

17.80%

8

19.00%

No response

22

48.90%

0

0.00%

Missing

6

13.30%

4

9.50%

Total

45

100.00%

42

100.00%

Back to article page